Prasinezumab
Mid-stage
active
recruiting
CT.gov grounded
High-visibility Parkinson's program targeting alpha-synuclein pathology.
Program overview
- Mechanism
- anti-alpha-synuclein antibody
- Modality
- monoclonal antibody
- Phase
- Mid-stage
- Status
- active
- Recruitment
- recruiting
- Confidence
- medium
- Watch priority
- 2
- Last verified
- 20 Apr 2026
Sponsor and trial identifiers
- Sponsor
- Prothena / Roche
- Trial IDs
- NCT07174310, NCT04777331
ClinicalTrials.gov exact matches: NCT07174310, NCT04777331
Regions and recruitment
United States
Australia
Austria
Brazil
Canada
China
Denmark
Germany
Italy
Mexico
Poland
Portugal
South Korea
Spain
Taiwan
United Kingdom
France
Luxembourg
Indication tags
Parkinson's
Milestones and catalysts
- Last milestone
- One of the best-known disease-modification programs in Parkinson's still in active follow-up.
- Next expected catalyst
- Further progression and functional readouts.
Related pages
Disease hub
Parkinson's disease hub
Disease-specific views with programs, mechanisms, and related context.
Related programs
Each card explains why it is here so you can read the overlap at a glance.
Mid-stage
active
active, not recruiting
A genetically targeted Parkinson's program that fits the monitor's mechanism-first framing well.
- Mechanism
- GCase pathway modulation
- Modality
- small molecule
- Next catalyst
- Further efficacy and pharmacodynamic data in GBA-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Early / Mid-stage
active
active, not recruiting
Gene-therapy Parkinson's program that gives the watchlist a cleaner exact-grounded GBA1 entry.
- Mechanism
- GBA1 gene replacement
- Modality
- AAV gene therapy
- Next catalyst
- Further safety and biomarker interpretation in GBA1-associated Parkinson's disease.
- Last verified
- 20 Apr 2026
Mid-stage
completed
completed
Mechanism-led repurposing program that keeps the Parkinson's pipeline from being only antibody and device narratives.
- Mechanism
- glucocerebrosidase support / lysosomal modulation
- Modality
- small molecule repurposing
- Next catalyst
- Whether clinical and biomarker read-throughs justify a larger disease-modification push.
- Last verified
- 20 Apr 2026
Mid-stage
completed
completed
Parkinson's program with direct mechanistic relevance to alpha-synuclein biology rather than only symptomatic management.
- Mechanism
- alpha-synuclein misfolding inhibition
- Modality
- small molecule
- Next catalyst
- Mostly interpretive now, but still important for understanding how far small-molecule alpha-syn strategies can go.
- Last verified
- 20 Apr 2026